September 23, 2011 (London, United Kingdom) — Advisors for the European Medicines Agency (EMA) have paved the way for two new indications for rivaroxaban (Xarelto, Bayer) in Europe. The EMA's ...

In stable patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with rivaroxaban 20 mg once daily did not improve clinical outcomes but did increase bleeding ...

Dear Dr. Roach: I am an 81-year-old female who has been on Xarelto for years due to my deep vein thrombosis (DVT). I also have an inferior vena cava (IVC) filter. I read that low-dose aspirin (325 mg) ...

For hospitalized COVID-19 patients with a high risk of venous thromboembolism (VTE) and/or elevated D-dimer levels, along with a low risk of bleeding, use of rivaroxaban 10 mg/day for 35 days after ...

NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...

The FINANCIAL — Janssen Research & Development, LLC announced the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications filed on ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

Lupin has received the Food and Drug Administration’s green light for rivaroxaban tablets, in 10 mg, 15 mg and 20 mg, which is the generic of Janssen’s Xarelto. This product will be manufactured at ...